RG 7112

Drug Profile

RG 7112

Alternative Names: R 1772; R-7112; RG-7112; RO-5045337

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Haematological malignancies; Liposarcoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 26 Jun 2017 Roche completes a phase I trial in Haematological malignancies and Solid tumours in USA, Canada and France (NCT01677780)
  • 30 Nov 2013 Roche completes a phase I trial in Acute myeloid leukaemia (combination therapy) in USA, Canada, France, Italy and the UK (NCT01635296)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top